BeiGene
BGNE
#964
Rank
C$28.96 B
Marketcap
$264.74
Share price
0.49%
Change (1 day)
22.96%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

EPS for BeiGene (BGNE)

EPS in 2023 (TTM): -$22.50

According to BeiGene 's latest financial reports the company's current EPS (TTM) is -$23.85. In 2022 the company made an earnings per share (EPS) of -$27.76 a decrease over its 2021 EPS that were of -$21.80.

EPS history for BeiGene from 2015 to 2023

Annual EPS

Year EPS Change
2023 (TTM)-$22.50-18.94%
2022-$27.7627.35%
2021-$21.80-19.96%
2020-$27.2420.81%
2019-$22.5531.52%
2018-$17.14417.57%
2017-$3.31-37.16%
2016-$5.27158.95%
2015-$2.04

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
-$1.43-93.99%๐Ÿ‡บ๐Ÿ‡ธ USA
-$0.39-98.38%๐Ÿ‡บ๐Ÿ‡ธ USA